Bhattacharyya, Gouri Shankar
Doval, Dinesh Chandra
Chacko, Raju Titus
AffiliationTata Memorial Hospital, Mumbai, India. firstname.lastname@example.org
MetadataShow full item record
AbstractINTRODUCTION: Treatment options are limited in patients with advanced or refractory non-small cell lung cancer and lead to suboptimal outcome and/or benefit. The epidermal growth factor tyrosine kinase inhibitor gefitinib (IRESSA) has been approved in many countries. Increased responsiveness to gefitinib has been demonstrated in particular subsets of patients, for example never smokers and patients of Asian origin. However, to date, little is known of its use specifically in patients from India. METHODS: Retrospective ad hoc analysis of clinical data from experience with gefitinib in patients with advanced NSCLC from India enrolled in the IRESSA Survival Evaluation in Lung (ISEL) study (n = 77) or included in the gefitinib expanded-access program in India (n = 133). RESULTS: Among Indian patients enrolled in the ISEL study, median survival was 6.4 months with gefitinib and 5.1 month with placebo. The objective response rate in Indian patients was 14% with gefitinib versus 0% with placebo. In ISEL, tolerability data from Indian patients were consistent with the overall study population. In the Indian gefitinib expanded-access program, median survival was 6 months and gefitinib was well tolerated. CONCLUSIONS: Gefitinib seems well tolerated in Indian patients with advanced NSCLC, with some clinical benefit observed.
CitationClinical experience with gefitinib in Indian patients. 2008, 3 (4):380-5 J Thorac Oncol
JournalJournal of Thoracic Oncology
- Gefitinib (IRESSA) in patients of Asian origin with refractory advanced non-small cell lung cancer: subset analysis from the ISEL study.
- Authors: Chang A, Parikh P, Thongprasert S, Tan EH, Perng RP, Ganzon D, Yang CH, Tsao CJ, Watkins C, Botwood N, Thatcher N
- Issue date: 2006 Oct
- A phase II trial of gefitinib monotherapy in chemotherapy-naïve patients of 75 years or older with advanced non-small cell lung cancer.
- Authors: Ebi N, Semba H, Tokunaga SJ, Takayama K, Wataya H, Kuraki T, Yamamoto H, Akamine SJ, Okamoto I, Nakanishi Y, Lung Oncology Group in Kyushu, Japan.
- Issue date: 2008 Oct
- Detection of epidermal growth factor receptor mutations in plasma by mutant-enriched PCR assay for prediction of the response to gefitinib in patients with non-small-cell lung cancer.
- Authors: He C, Liu M, Zhou C, Zhang J, Ouyang M, Zhong N, Xu J
- Issue date: 2009 Nov 15
- First-line gefitinib treatment for patients with advanced non-small cell lung cancer with poor performance status.
- Authors: Lee YJ, Kim HT, Han JY, Yun T, Lee GK, Kim HY, Sung JH, Lee JS
- Issue date: 2010 Mar
- Safety and efficacy of gefitinib treatment in elderly patients with non-small-cell lung cancer: Okayama Lung Cancer Study Group experience.
- Authors: Hotta K, Ueoka H, Kiura K, Tabata M, Ogino A, Umemura S, Harita S, Gemba K, Yonei T, Bessho A, Maeda T, Tanimoto M
- Issue date: 2005